tbuckley/cabot-search huggingface dataset:
Abstract 9870: Covid-19 is Associated with Increased In-Hospital Mortality in Patients Hospitalized for Acute Myocardial Infarction: A Meta-Analysis of Observational Studies
Authors: Nischit Baral, Sangeeta Poudel, Asmita Itani, Saroj A Adhikari Yadav, Swotantra Gautam, Mohamed Gismalla, Basel Abdelazeem, Sakiru Isa, Joshua Christy, Abdul Rafae, Bandana Ranabhat, Pramod Savarapu, Arvind Kunadi, Tripti Gupta, Yashashwi Pokharel
Journal: Circulation (2021)

Introduction: Corona Virus Disease 2019 (COVID-19) Infection is associated with acute cardiac injury. We examined the risk of in-hospital mortality in patients with concomitant COVID-19 infection and acute myocardial infarction (AMI) as compared to patients with AMI without COVID-19 infection. Hypothesis: COVID-19 is associated with increased in-hospital mortality in patients hospitalized for AMI. Methods: We conducted a systematic review and meta-analysis of published articles from January 2019 to May 2021. Literature search was performed on PubMed, Cochrane database, Embase, and Web of Science. We included studies done in patients with index hospitalization for AMI. Patients with positive COVID-19 Polymerase Chain Reaction were considered to have COVID-19 infection. We used random-effects model using the risk ratio (RR) and 95% confidence interval (CI). We used I squared test to assess for heterogeneity. Results: After assessing 20 articles for full text screen for eligibility, four cohort studies met our inclusion criteria. There were a total of 1918 participants in both COVID and non-COVID groups, who were hospitalized for AMI between February 1, 2020 to June 30, 2020. 168 participants (8.76%) had concomitant COVID-19. Confounders were adjusted in only one article. Most of the confounders like age, sex, race and BMI were similar in both groups but co-morbidities were higher in COVID group in all four studies. 42 patients (61%) with COVID-19 and 69 patients (0.96%) with no COVID-19 died in hospital. Pooled data from the four studies showed patients with AMI and COVID-19 infection had more than six times increased risk of in-hospital mortality compared with patients who had AMI but no COVID-19 infection (RR 6.17, 95% CI: 4.11-9.26; I 2 =9%, P&lt;0.00001). Conclusions: Our study shows that COVID-19 infection is associated with increased in-hospital mortality in patients hospitalized for AMI. Our limitations include higher comorbidities in COVID group, unable to capture all COVID patients, and high risk of bias with cohort studies. Whether patients with concomitant COVID-19 infection and AMI will benefit from unique management approaches should be further examined.
Abstract 14459: Ten Year Evolving Profile of Black Americans With Myocardial Infarctions
Authors: Jaime Murillo, Omid Ameli, Henry Henk, Deneen Vojta
Journal: Circulation (2021)

Background: Racial disparities in the management and outcomes of myocardial infarction have been widely reported. Overall, the rate of cardiovascular (CV) death has risen since 2010 while hospitalization rates remain flat. Here, we provide a comprehensive analysis, using a large database, of the evolving profile of Black Americans (BA) who suffered myocardial infarctions (MI) over the past 10 years and compared BA to the non-Black (non-BA) population. We also describe the change in their characteristics between 2 continuous 5-year periods (2010-14, 2015- 19) with the goal of identifying opportunities for care improvement. Methods: We used the OptumLabs Data Warehouse EHR data. Acute MI cases were based on discharge diagnosis codes for adults &gt; 35 years of age between 1/1/2010 and 12/31/2019. A single individual could have had multiple MI’s. Data were analyzed descriptively. Results: A total of 36M annual observations were analyzed which included 129,146 MI’s with complete EHR data. MI’s among BA patients comprised 8.7% of the total in the 1 st period and went up to 10.4% in the 2 nd period.The main characteristics between BA and non-BA cases and between periods are shown in the table. In general, BA MI patients were younger than non-BA (57% vs 40% were &lt;65). Conclusion: Compared to non-Blacks, Black patients with myocardial infarctions over the past 10 years exhibit a profile characterized by: MI’s at a younger age, almost half female, more DM, higher cholesterol and blood pressure levels, higher rate of smoking, more are Medicaid and ¾ live in the South.When comparing only Black patients between 2010-14 and 2015-2019 there was a marked increase in total MI’s, mostly in the 55-75 age range, increased diabetes, smoking and rising SBP levels.The description of an evolving profile among Blacks with MI’s could, at least partly, explain the rising trend of CV mortality, identify potential gaps in care and the need to design new forms to detect subclinical atherosclerosis.
The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial
Authors: Yuankai Shi, Yan Qin, Yongping Song, Keshu Zhou, Hui Zhou, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang
Journal: Blood (2021)
Abstract 9122: Polyvalvular Heart Disease in Children Associated With FilaminA Mutations
Authors: Ellen S Deng, Sarah B Araten, Jessica M Yamada, Michelle L Walsh, Abbe Lai, Sangita Choudhury, Ming Chen
Journal: Circulation (2021)

Introduction: FilaminA ( FLNA ), an X-linked gene encoding an actin binding protein, is one of the only known causative genes for periventricular nodular heterotopia (PVNH) and mitral valve (MV) prolapse. FLNA mutations have been well associated with familial MV prolapse and polyvalvular disease in adults. There is limited data, however, on the type and distribution of valve disease in children with FLNA mutations. We aim to assess the frequency of polyvalvular disease in a predominantly pediatric cohort. Methods: We retrospectively enrolled subjects from a large registry at Boston Children’s Hospital of patients and families with PVNH and FLNA mutations with at least one transthoracic echo and clinical phenotyping of their cardiovascular and neurologic status. Additionally, data from published subjects with FLNA mutations and PVNH were included in the cohort. Imaging data about valvular heart disease were extracted for all subjects. Results: 165 patients with FLNA mutations formed our cohort (128 F, median age 9 yrs, range 0-71 yrs), with 53% ≤ 21 yrs. Valve disease was the most common type of isolated structural disease, presenting in 58% (62/110) of FLNA patients with congenital heart disease. Of these patients, 45% (28/62, 10 M) had polyvalvular disease and 36% (22/62, 8 M) underwent cardiac surgery. MV prolapse or dysplasia was present in 60% (37/62) of patients. Aortic valve abnormalities were equally common, also occurring in 60% (37/62) of patients (e.g. bicuspid aortic valves and aortic valve prolapse). Notably, tricuspid valve dysplasia did not occur independently (n=0), and always presented with involvement of other cardiac valves. In patients with polyvalvular disease, mitral and aortic valves were most commonly involved together, occurring in 23% (14/62) of patients. Males with FLNA mutations were more likely to have polyvalvular disease with more severe clinical phenotypes. Conclusions: In this largest cohort of predominantly children with FLNA mutations, FLNA patients frequently have polyvalvular disease on echocardiography. When polyvalvular disease is detected especially involving the tricuspid valve, pediatric cardiologists should consider genetic testing for FLNA mutations as a potential contributor of disease.
Abstract 11530: Cardiovascular Risk Profile and Preterm Birth by Maternal Nativity in Racially Diverse, Urban, Low Income Women in the United States
Authors: Ellen Boakye, Yaa A Kwapong, Olufunmilayo H Obisesan, Lochan M Shah, S. Michelle Ogunwole, Arthur J Vaught, Khurram Nasir, Wendy Bennett, Andreea Creanga, Roger S Blumenthal, Michael J Blaha, Xiaobin Wang, Garima Sharma
Journal: Circulation (2021)

Introduction: Preterm Birth (PTB) is an independent risk factor for future cardiovascular disease (CVD). Nativity-related disparities in CVD risk profile and risk of PTB have been shown among non-Hispanic Black (NHB) women; however, studies exploring these disparities among women of other races are limited. We hypothesized that foreign-born NHB, White, and Hispanic women will have better CVD risk profile and lower risk of PTB compared to their US-born counterparts. Methods: We utilized data from 6096 women with mean age 27.5(±6.3) years in the Boston Birth Cohort who self-identified as NHB (2699), White (997), or Hispanic (2400). We examined differences in sociodemographic characteristics and CVD risk factors such as smoking, obesity, and hypertension by nativity status. Using multivariable logistic regression models, we examined the association of nativity and length of U.S. residence with PTB by race. Results: Of the total sample, 27.2% delivered preterm (29.1%, 29.8%, and 24.1% among NHB, White, and Hispanic women, respectively). Compared to foreign-born women, US-born women in each of the three racial groups were younger and more likely to be obese, single, smoke in pregnancy, and report severe stress. After adjusting for sociodemographic characteristics and CVD risk factors, foreign-born NHB women had lower odds of PTB compared to U.S-born NHB women (adjusted odds ratio, aOR: 0.79; 95%CI: 0.65-0.97). Similarly, foreign-born Hispanic women had lower odds of PTB compared to U.S-born Hispanic women (aOR: 0.72; 95%CI: 0.56-0.93). In all 3 racial groups, shorter (&lt;10 years), but not longer (≥10 years) length of U.S. residence was associated with lower odds of PTB. (Figure) Conclusions: US-born women in all three racial groups had a higher prevalence of CVD risk factors including smoking, obesity, and stress, compared to foreign-born women. The “foreign-born advantage” which is protective of PTB was not observed among foreign-born women with ≥10 years of U.S. stay.
Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib
Authors: Mark Roschewski, James D. Phelan, Stefania Pittaluga, Christopher Melani, Rahul Lakhotia, Jacob J. Chabon, Jagan R. Muppidi, Kathryn A. Lurain, Jillian Simard, Amynah Pradhan, Amy Hillsman, Madeline Rilko, Seth M. Steinberg, George W. Wright, Da Wei Huang, Yandan Yang, Michail S. Lionakis, Alexander Bagaev, Ekaterina Postovalova, Mark Meerson, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, David M. Kurtz, Ash A. Alizadeh, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood (2021)
To be malnourished or not to be malnourished: that is the question!
Authors: Stéphane Jouneau, Mallorie Kerjouan, Ronan Thibault
Journal: European Respiratory Journal (2021)

<b>Physicians in charge of patients with chronic respiratory diseases, including chronic pulmonary aspergillosis, should be aware of the high prevalence of malnutrition. Despite simple diagnosis, it is underdiagnosed and associated with worse prognosis.</b>https://bit.ly/3uEgEJn
Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE ® Construct Mediated Cytotoxicity
Authors: Maryam Kazerani Pasikhani, Anetta Marcinek, Bettina Brauchle, Jonathan Jonas Taylor, Helena Domínguez Moreno, Maria Solovey, Frank Ziemann, Nora Zieger, Andrea Terrasi, Benjamin Tast, Karsten Spiekermann, Klaus H. Metzeler, Tobias Straub, Gunnar Schotta, Roman Kischel, Veit L Buecklein, Marion Subklewe
Journal: Blood (2021)
<i>Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects</i>
Authors: Marco Ruella, Mireia Uribe-Herranz, Silvia Beghi, Kalpana Parvathaneni, Nektarios Kostopoulos, Guido Ghilardi, Kimberly Amelsberg, Yong Gu Gu Lee, Raymone Pajarillo, Noelle V Frey, Simon F Lacey, Khatuna Gabunia, John Scholler, Elise A Chong, Carl H June, David L. Porter, Stephen J. Schuster, Vijay Bhoj, Andrea Facciabene
Journal: Blood (2021)
USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable,
Authors: Guy Olson, Walter Jeske, Omer Iqbal, Ambar Farooqui, Fakiha Siddiqui, Debra Hoppensteadt, Ahmed Kouta, Jawed Fareed, Eduardo Ramacciotti
Journal: Blood (2021)
High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial
Authors: Moritz Fürstenau, Anke Schilhabel, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Eugen Tausch, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Marinus H.J. Van Oers, Caspar Da Cunha-Bang, Christian H. Geisler, Stephan Stilgenbauer, Monika Brüggemann, Michael Hallek, Matthias Ritgen, Barbara Eichhorst
Journal: Blood (2021)
Production of Anti-Spike Antibodies in Response to COVID Vaccine in Lymphoma Patients
Authors: Alexandra Della Pia, Gee Youn Kim, Jaeil Ahn, Yanzhi Liu, Brittany Lukasik, Anamta Contractor, Amin Krushna, Lakshmi Ayyagari, Michael Koropsak, Lori A. Leslie, Andre H. Goy, Tatyana A. Feldman, Andrew Ip
Journal: Blood (2021)
Eliminating Panglossian thinking in development of AAV therapeutics
Authors: Radoslaw Kaczmarek, Glenn F. Pierce, Declan Noone, Brian O'Mahony, David Page, Mark W. Skinner
Journal: Molecular Therapy (2021)

The US Food and Drug Administration (FDA) held a 2-day meeting (September 2–3, 2021) of the Cellular, Tissue and Gene Therapies Advisory Committee to consider toxicity risks of adeno-associated virus (AAV) vector-associated gene therapy products including a review of oncogenicity risks due to vector genome integration and safety issues identified during preclinical and/or clinical evaluation.
Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning
Authors: Uday Prakash Kulkarni, Aswin Anand Pai, Kavitha M Lakshmi, Sushil Selvarajan, Sharon Lionel, Anup J Devasia, Anu Korula, Fouzia NA, Eunice Sindhuvi, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George, Poonkuzhali Balasubramanian
Journal: Blood (2021)
Abstract 9372: Association of Past Discrimination With Medication Adherence and Blood Pressure in the HYpertension and VALUEs (HYVALUE) Trial
Authors: Rajiv Patel, Laura Helmkamp, Rebecca Hanratty, Suma Vupputuri, Irene V Blair, Julie Maertens, John Steiner, Edward P Havranek, L. Miriam Dickinson, Stacie Daugherty
Journal: Circulation (2021)

Introduction: Racial discrimination has been associated with worse health outcomes, including blood pressure (BP). Using data from the HYVALUE trial, we examined whether past racial discrimination was associated with systolic blood pressure (SBP), diastolic blood pressure (DBP), or BP medication adherence, for Black and White patients. Methods: Black and White patients with hypertension (HTN) were enrolled from 2017-2019. At enrollment, participants were asked how often they had experienced discrimination in any or the healthcare setting based on their race (1=never, 5=all the time). SBP and DBP were measured and anti-HTN medication adherence in the last 6 months was extracted from pharmacy fill data. Generalized linear models tested the associations of discrimination with SBP, DBP, and adherence in separate models adjusting for clinic, age, gender, and number of BP medications; participant race was included as an interaction term in final models. Results: Among the 925 participants (55% Black, 47% ≥64 years of age, 60% Female), racial discrimination in any setting was reported as more frequent by Black than White participants (Median (IQR): 3.0 (2.0-4.0) vs. 1.0 (1.0-2.0), p&lt;.001). Discrimination in healthcare was reported as less common overall, but more frequent for Black than White participants (Median (IQR): 1.0 (1.0-2.0) vs. 1.0 (1.0-1.0), p&lt;.001). In adjusted models, discrimination in any setting was not significantly associated with SBP (β= .08, p= .88;), DBP (β= .22, p=0.51) or adherence (β= -.13, p=.08); discrimination in healthcare was not associated with SBP (β= -.35, p=.66), DBP (β= -.29, p=.56), or adherence (β= -.01, p=.88). Participant race did not moderate any of these results (all p &gt; 0.05). Conclusions: In this study, 2 single-item measures of past racial discrimination in any or healthcare-settings were not associated with BP or medication adherence, and these results did not differ by race. Because the HYVALUE trial was embedded in health care systems, discrimination may be under-reported or patients being treated for HTN may be less likely to show effects of discrimination on related outcomes. Additional studies are needed to examine prospective associations between discrimination and BP outcomes.
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
Authors: Chun-Hwei Tai, Ni-Chung Lee, Yin-Hsiu Chien, Barry J. Byrne, Shin-Ichi Muramatsu, Sheng-Hong Tseng, Wuh-Liang Hwu
Journal: Molecular Therapy (2021)

Aromatic L-amino acid decarboxylase deficiency results in decreased neurotransmitter levels and severe motor dysfunction. Twenty-six patients without head control received bilateral intraputaminal infusions of a recombinant adeno-associated virus type 2 vector containing the human aromatic L-amino acid decarboxylase gene (eladocagene exuparvovec) and have completed 1-year evaluations. Rapid improvements in motor and cognitive function occurred within 12 months after gene therapy and were sustained during follow-up for >5 years. An increase in dopamine production was demonstrated by positron emission tomography and neurotransmitter analysis. Patient symptoms (mood, sweating, temperature, and oculogyric crises), patient growth, and patient caretaker quality of life improved. Although improvements were observed in all treated participants, younger age was associated with greater improvement. There were no treatment-associated brain injuries, and most adverse events were related to underlying disease. Post-surgery complications such as cerebrospinal fluid leakage were managed with standard of care. Most patients experienced mild to moderate dyskinesia that resolved in a few months. These observations suggest that eladocagene exuparvovec treatment for aromatic L-amino acid decarboxylase deficiency provides durable and meaningful benefits with a favorable safety profile. Aromatic L-amino acid decarboxylase deficiency results in decreased neurotransmitter levels and severe motor dysfunction. Twenty-six patients without head control received bilateral intraputaminal infusions of a recombinant adeno-associated virus type 2 vector containing the human aromatic L-amino acid decarboxylase gene (eladocagene exuparvovec) and have completed 1-year evaluations. Rapid improvements in motor and cognitive function occurred within 12 months after gene therapy and were sustained during follow-up for >5 years. An increase in dopamine production was demonstrated by positron emission tomography and neurotransmitter analysis. Patient symptoms (mood, sweating, temperature, and oculogyric crises), patient growth, and patient caretaker quality of life improved. Although improvements were observed in all treated participants, younger age was associated with greater improvement. There were no treatment-associated brain injuries, and most adverse events were related to underlying disease. Post-surgery complications such as cerebrospinal fluid leakage were managed with standard of care. Most patients experienced mild to moderate dyskinesia that resolved in a few months. These observations suggest that eladocagene exuparvovec treatment for aromatic L-amino acid decarboxylase deficiency provides durable and meaningful benefits with a favorable safety profile.
Clinical characteristics, hospitalisation and mortality rates of COVID-19 among patients with coeliac disease in the USA: a multicentre network study
Authors: Emad Mansoor, Muhammed Mustafa Alikhan, Jaime Abraham Perez, Kayla Schlick, Mohannad Abou Saleh, Alberto Rubio-Tapia
Journal: Gut (2021)

We read with interest the work by Belli et al 1 regarding outcomes of COVID-19 in liver transplant candidates. The authors concluded that liver transplant candidates were at risk of early death, especially those with decompensated cirrhosis and model for end-stage liver disease score≥15.

Similarly, patients with coeliac disease (CD) are a population of interest in regards to clinical outcomes after a diagnosis of COVID-19. Although the evidence of an impact of other chronic disorders on the outcome of COVID-19 is emerging, the consequences of COVID-19 infection in individuals with CD remain uncertain.2–4 We sought to define the rates of hospitalisation, mortality, thrombosis or intensive care unit (ICU) requirement in individuals with CD and COVID-19.

We used a large healthcare research network (TriNetX) to compile the electronic medical records of adult patients (age ≥18 years) with CD and confirmed COVID-19 infection (CD cohort) from 51 healthcare organisations in the USA, between 1 January 2020 and 7 July 2021. Within this same time period, we also identified COVID-19 positive patients with no history of CD (non-CD cohort). The definition of …
Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers
Authors: Dorian Forte, Roberto Maria Pellegrino, Francesco Fabbri, Ivan Vannini, Samantha Bruno, Giulia Corradi, Rafael J. Argüello, Gianluca Cristiano, Sandra Buratta, Lorena Urbanelli, Carla Emiliani, Michele Cavo, Antonio Curti
Journal: Blood (2021)